Advanced

Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

Duarte-Salles, Talita; Misra, Sandeep; Stepien, Magdalena; Plymoth, Amelie; Muller, David; Overvad, Kim; Olsen, Anja; Tjønneland, Anne; Baglietto, Laura and Severi, Gianluca, et al. (2016) In Cancer Prevention Research 9(9). p.758-765
Abstract

We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between prediagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function, and a-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to calculate multivariable odds ratio (OR) and 95%... (More)

We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between prediagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function, and a-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to calculate multivariable odds ratio (OR) and 95% confidence intervals (95% CI) for OPN levels in relation to HCC. Receiver operating characteristics curves were constructed to determine the discriminatory accuracy of OPN alone or in combination with other liver biomarkers in the prediction of HCC. OPN levels were positively associated with HCC risk (per 10% increment, ORmultivariable = 1.30; 95% CI, 1.14-1.48). The association was stronger among cases diagnosed within 2 years of follow-up. Adding liver function tests to OPN improved the discriminatory performance for subjects who developed HCC (AUC = 0.86). For cases diagnosed within 2 years, the combination of OPN and AFP was best able to predict HCC risk (AUC = 0.88). The best predictive model for HCC in this low-risk population is OPN in combination with liver function tests. Within 2 years of diagnosis, the combination of OPN and AFP best predicted HCC development, suggesting that measuring OPN and AFP could identify high-risk groups independently of a liver disease diagnosis.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Prevention Research
volume
9
issue
9
pages
8 pages
publisher
American Association for Cancer Research
external identifiers
  • scopus:84987879295
  • wos:000383090500006
ISSN
1940-6207
DOI
10.1158/1940-6207.CAPR-15-0434
language
English
LU publication?
yes
id
9d6ddd16-e3c6-42cf-abe5-44f8bbd4d98f
date added to LUP
2016-10-06 09:39:35
date last changed
2017-10-16 12:48:21
@article{9d6ddd16-e3c6-42cf-abe5-44f8bbd4d98f,
  abstract     = {<p>We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between prediagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function, and a-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to calculate multivariable odds ratio (OR) and 95% confidence intervals (95% CI) for OPN levels in relation to HCC. Receiver operating characteristics curves were constructed to determine the discriminatory accuracy of OPN alone or in combination with other liver biomarkers in the prediction of HCC. OPN levels were positively associated with HCC risk (per 10% increment, ORmultivariable = 1.30; 95% CI, 1.14-1.48). The association was stronger among cases diagnosed within 2 years of follow-up. Adding liver function tests to OPN improved the discriminatory performance for subjects who developed HCC (AUC = 0.86). For cases diagnosed within 2 years, the combination of OPN and AFP was best able to predict HCC risk (AUC = 0.88). The best predictive model for HCC in this low-risk population is OPN in combination with liver function tests. Within 2 years of diagnosis, the combination of OPN and AFP best predicted HCC development, suggesting that measuring OPN and AFP could identify high-risk groups independently of a liver disease diagnosis.</p>},
  author       = {Duarte-Salles, Talita and Misra, Sandeep and Stepien, Magdalena and Plymoth, Amelie and Muller, David and Overvad, Kim and Olsen, Anja and Tjønneland, Anne and Baglietto, Laura and Severi, Gianluca and Boutron-Ruault, Marie Christine and Turzanski-Fortner, Renee and Kaaks, Rudolf and Boeing, Heiner and Aleksandrova, Krasimira and Trichopoulou, Antonia and Lagiou, Pagona and Bamia, Christina and Pala, Valeria and Palli, Domenico and Mattiello, Amalia and Tumino, Rosario and Naccarati, Alessio and Bueno-De-Mesquita, H. B. and Peeters, Petra H. and Weiderpass, Elisabete and Quiros, J. Ramôon and Agudo, Antonio and Sanchez-Cantalejo, Emilio and Ardanaz, Eva and Gavrila, Diana and Dorronsoro, Miren and Werner, Mårten and Hemmingsson, Oskar and Ohlsson, Bodil and Sjöberg, Klas and Wareham, Nicholas J. and Khaw, Kay Tee and Bradbury, Kathryn E. and Gunter, Marc J. and Cross, Amanda J. and Riboli, Elio and Jenab, Mazda and Hainaut, Pierre and Beretta, Laura},
  issn         = {1940-6207},
  language     = {eng},
  month        = {09},
  number       = {9},
  pages        = {758--765},
  publisher    = {American Association for Cancer Research},
  series       = {Cancer Prevention Research},
  title        = {Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population},
  url          = {http://dx.doi.org/10.1158/1940-6207.CAPR-15-0434},
  volume       = {9},
  year         = {2016},
}